The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
暂无分享,去创建一个
M. Ladanyi | R. Somwar | E. de Stanchina | M. Mattar | M. Vojnic | I. Khodos | L. Delasos | I. Odintsov | E. Gladstone | Zebing Liu | W. J. Sisso | A. Lui | R. Kurth | E. M. Sisso | S. Leland
[1] A. Drilon,et al. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. , 2020, The oncologist.
[2] Edward S. Kim,et al. Characterization of NRG1 gene fusion events in solid tumors. , 2020 .
[3] M. Ladanyi,et al. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions , 2020, Clinical Cancer Research.
[4] B. Sola,et al. The double dealing of cyclin D1 , 2019, Cell cycle.
[5] M. Ladanyi,et al. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR‐Mutated Lung Cancers , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] Edward S. Kim,et al. Detection of NRG1 Gene Fusions in Solid Tumors , 2019, Clinical Cancer Research.
[7] L. Sequist,et al. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. , 2019, The oncologist.
[8] P. Gros,et al. Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade. , 2018, Cancer cell.
[9] A. Rossi,et al. Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression , 2017, Oncotarget.
[10] M. Ladanyi,et al. Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. , 2018, Cancer discovery.
[11] Jacob K. Asiedu,et al. The Drug Repurposing Hub: a next-generation drug library and information resource , 2017, Nature Medicine.
[12] V. Grantcharova,et al. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121) , 2017, npj Systems Biology and Applications.
[13] M. Ladanyi,et al. Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations , 2016, Clinical Cancer Research.
[14] M. Antoine,et al. NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma , 2016, Cancer medicine.
[15] H. You,et al. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung , 2016, Oncotarget.
[16] S. Leung,et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[17] V. Beral,et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.
[18] Karen D. Cowden Dahl,et al. In vivo tumor growth of high-grade serous ovarian cancer cell lines. , 2015, Gynecologic oncology.
[19] P. Wei,et al. BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs , 2015, Clinical Cancer Research.
[20] Roman K. Thomas,et al. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer , 2014, Clinical Cancer Research.
[21] S. Chandarlapaty,et al. Molecular Pathways: HER3 Targeted Therapy , 2014, Clinical Cancer Research.
[22] I. Petersen,et al. CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.
[23] Birgit Schoeberl,et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. , 2010, Cancer cell.
[24] Birgit Schoeberl,et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. , 2010, Cancer research.
[25] H. Varmus,et al. Identification and Preliminary Characterization of Novel Small Molecules That Inhibit Growth of Human Lung Adenocarcinoma Cells , 2009, Journal of biomolecular screening.
[26] V. Grantcharova,et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.
[27] J. Minna,et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.
[28] K. Akashi,et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice , 2005 .
[29] K. Akashi,et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. , 2005, Blood.
[30] John J. Peterson,et al. Estimation of Confidence Intervals for Area Under the Curve from Destructively Obtained Pharmacokinetic Data , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[31] H. Lemke,et al. Monitoring of cell viability and cell growth in a hollow-fiber bioreactor by use of the dye Alamar Blue. , 2001, Journal of immunological methods.
[32] D. Birnbaum,et al. γ-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line , 1999, Oncogene.
[33] D. Birnbaum,et al. gamma-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line. , 1999, Oncogene.
[34] M. Sliwkowski,et al. γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175 , 1997, Oncogene.
[35] A. Long,et al. A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.